Karuna Therapeutics, Inc., A Bristol Myers Squibb Company

This study is testing if an investigational drug called KarXT can help prevent the return of distressing psychosis symptoms like hallucinations and delusions in people with Alzheimer's disease. It will involve about 410 participants aged 55-90 who have these symptoms. The main go…

This study aims to understand the long-term safety of KarXT for teenagers with schizophrenia and children with autism-related irritability. It follows 400 young participants who have already completed earlier studies with these medications. Researchers will monitor side effects a…

This study aims to check the long-term safety of adding a new drug called KarXT to the current antipsychotic medications of adults with schizophrenia. It will follow about 280 people for one year to see how well they tolerate the combined treatment. The goal is to see if this add…

This study is testing whether a medication called KarXT can safely reduce distressing symptoms like hallucinations and delusions in people with Alzheimer's disease. Researchers will compare KarXT against a placebo in about 406 adults aged 55-90 who have Alzheimer's and moderate t…